000119954 001__ 119954
000119954 005__ 20240319081020.0
000119954 0247_ $$2doi$$a10.1016/j.schres.2022.05.021
000119954 0248_ $$2sideral$$a129961
000119954 037__ $$aART-2022-129961
000119954 041__ $$aeng
000119954 100__ $$aSegura, Àlex G.
000119954 245__ $$aMetabolic polygenic risk scores effect on antipsychotic-induced metabolic dysregulation: A longitudinal study in a first episode psychosis cohort; 35659654
000119954 260__ $$c2022
000119954 5060_ $$aAccess copy available to the general public$$fUnrestricted
000119954 5203_ $$aObjective: Metabolic syndrome is a health-threatening condition suffered by approximately one third of schizophrenia patients and largely attributed to antipsychotic medication. Previous evidence reports a common genetic background of psychotic and metabolic disorders. In this study, we aimed to assess the role of polygenic risk scores (PRSs) on the progression of the metabolic profile in a first-episode psychosis (FEP) cohort. Method: Of the 231 FEP individuals included in the study, 192–220 participants were included in basal analysis and 118–179 in longitudinal 6-month models. Eleven psychopathologic and metabolic PRSs were constructed. Basal and longitudinal PRSs association with metabolic measurements was assessed by statistical analyses. Results: No major association of psychopathological PRSs with the metabolic progression was found. However, high risk individuals for depression and cholesterol-related PRSs reported a higher increase of cholesterol levels during the follow-up (FDR = 0.023 for all analyses). Their effect was comparable to other well-established pharmacological and environmental risk factors (explaining at least 1.2% of total variance). Conclusion: Our findings provide new evidence of the effects of metabolic genetic risk on the development of metabolic dysregulation. The future establishment of genetic profiling tools in clinical procedures could enable practitioners to better personalize antipsychotic treatment selection and dosage. © 2022
000119954 540__ $$9info:eu-repo/semantics/openAccess$$aby-nc-nd$$uhttp://creativecommons.org/licenses/by-nc-nd/3.0/es/
000119954 590__ $$a4.5$$b2022
000119954 592__ $$a1.429$$b2022
000119954 591__ $$aPSYCHIATRY$$b45 / 143 = 0.315$$c2022$$dQ2$$eT1
000119954 593__ $$aPsychiatry and Mental Health$$c2022$$dQ1
000119954 591__ $$aPSYCHIATRY$$b57 / 154 = 0.37$$c2022$$dQ2$$eT2
000119954 593__ $$aBiological Psychiatry$$c2022$$dQ2
000119954 594__ $$a7.4$$b2022
000119954 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000119954 700__ $$aMartínez-Pinteño, Albert
000119954 700__ $$aGassó, Patricia
000119954 700__ $$aRodríguez, Natalia
000119954 700__ $$aBioque, Miquel
000119954 700__ $$aCuesta, Manuel J.
000119954 700__ $$aGonzález-Peñas, Javier
000119954 700__ $$aGarcía-Rizo, Clemente
000119954 700__ $$0(orcid)0000-0002-9098-655X$$aLobo, Antonio$$uUniversidad de Zaragoza
000119954 700__ $$aGonzález-Pinto, Ana
000119954 700__ $$aGarcía-Alcón, Alicia
000119954 700__ $$aRoldán, Alexandra
000119954 700__ $$aVieta, Eduard
000119954 700__ $$aCastro-Fornieles, Josefina
000119954 700__ $$aMané, Anna
000119954 700__ $$aSaiz, Jeronimo
000119954 700__ $$aBernardo, Miguel
000119954 700__ $$aMas, Sergi
000119954 700__ $$aGroup, PEPs
000119954 7102_ $$11007$$2745$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Psiquiatría
000119954 773__ $$g244 (2022), 101-110$$pSchizophr. res.$$tSCHIZOPHRENIA RESEARCH$$x0920-9964
000119954 8564_ $$s1114239$$uhttps://zaguan.unizar.es/record/119954/files/texto_completo.pdf$$yVersión publicada
000119954 8564_ $$s2329320$$uhttps://zaguan.unizar.es/record/119954/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000119954 909CO $$ooai:zaguan.unizar.es:119954$$particulos$$pdriver
000119954 951__ $$a2024-03-18-16:05:23
000119954 980__ $$aARTICLE